What sterile compounding means: inside the cleanroom

What sterile compounding means

Compounding is the practice of a licensed pharmacy preparing a medication to fit a specific prescription — measuring, combining, or adjusting ingredients into a particular strength or dosage form. Sterile compounding is the subset of that work reserved for preparations that must be free of microorganisms and, in many cases, of particulate matter and bacterial byproducts as well. Injectable medications, intravenous solutions, and preparations meant for the eye all fall into this category. This article describes the environments and processes involved in that work. It is educational only and is not medical advice.

The reason the bar is higher for these preparations comes down to how they enter the body. Skin and the digestive tract are among the body's natural barriers to microbes, and a medication taken by mouth or applied topically passes through those defenses. An injectable or intravenous preparation is introduced past them — into tissue or the bloodstream directly — so a contaminant present at the moment of preparation could reach places the body is not designed to defend at that point. Sterile compounding is, in essence, the set of controls designed to keep contamination from being introduced in the first place.

This is what separates sterile from non-sterile compounding. Non-sterile preparations such as capsules, creams, and oral liquids are made in clean but not classified environments, following one set of United States Pharmacopeia (USP) standards. Sterile preparations are made in controlled, classified spaces using defined techniques, following stricter USP standards. In the United States, the reference standard for how these preparations are made is USP General Chapter <797>.

The standard behind sterile preparation: USP <797>

The United States Pharmacopeia is a nongovernmental standards-setting organization, and its General Chapter <797> sets out requirements for compounded sterile preparations — often abbreviated CSPs. The chapter addresses:

• The facility
• The personnel
• The preparation process
• Environmental monitoring
• Testing
• Dating

State boards of pharmacy commonly reference or enforce these standards, and facilities operating under federal Current Good Manufacturing Practice align with them as well. The chapter is best understood as a framework for reducing contamination risk, not as a guarantee about any individual preparation.

A 2023 revision reorganized how sterile preparations are categorized. Earlier versions sorted preparations into low-, medium-, and high-risk levels; the revised chapter uses Categories 1, 2, and 3, defined primarily by the environment where a preparation is compounded and how long it is stored, rather than by preparation complexity alone. Higher categories carry more frequent monitoring and testing requirements. These distinctions govern how a pharmacy operates internally and are not something a patient chooses.

One concept that comes out of this framework is the beyond-use date, or BUD. A BUD describes the period during which a compounded preparation is expected to remain within its intended specifications when stored as directed. It is distinct from the expiration date printed on a mass-manufactured drug, and it is determined by factors such as the category of the preparation, the environment it was made in, and any sterility testing performed. Assigning and honoring a BUD is part of the pharmacy's professional responsibility, not the patient's.

Inside the cleanroom: air, isolation, and engineering controls

A cleanroom is a space classified by how clean its air is, measured under the ISO 14644-1 standard by counting airborne particles of a given size per volume of air. The cleaner the air, the lower the ISO class number. The actual compounding of a sterile preparation is meant to take place inside a primary engineering control — a device or zone designed to maintain ISO Class 5 air, the cleanest tier used in this work. Laminar airflow workbenches, biological safety cabinets, and compounding aseptic isolators are common examples, and each is built to bathe the critical work area in unidirectional, HEPA-filtered air.

That primary control does not sit in an ordinary room. It is typically housed in a layered environment: an ISO Class 7 buffer room that contains the compounding device, entered through an ISO Class 8 ante-room used for hand hygiene, gowning, and staging supplies. Each space is supplied with HEPA-filtered air and a controlled number of air changes per hour, so that the air grows progressively cleaner as a person moves from the ante-room toward the compounding zone. The layout is designed so that contaminants have several barriers to cross before reaching the preparation.

The engineering behind this is intended to do a specific job: unidirectional airflow is designed to sweep airborne particles away from the critical site rather than let them settle onto it, and HEPA filtration removes very fine particles from the incoming air. Pressure relationships between rooms are set so air tends to flow in the intended direction. These controls support the work, but they are understood to reduce risk only when paired with correct technique — a well-designed cleanroom does not make preparation sterile on its own.

Aseptic technique and the people doing the work

Aseptic technique is the term for the set of practices intended to avoid introducing microorganisms while a preparation is being made — how a person moves, where their hands are placed relative to the airflow, and how surfaces and materials are handled. It sits alongside the cleanroom rather than being replaced by it. In fact, the people in the room are understood to be the largest single source of contamination in sterile compounding, because skin, hair, and breath continually shed particles and microbes. Much of USP <797> is, in effect, about controlling that human factor.

This is why gowning and hand hygiene are so structured. Personnel follow a defined sequence for washing, garbing in gowns, masks, and gloves, and disinfecting gloved hands, and they are trained to position their hands and tools so as not to disrupt the clean airflow passing over the critical site. The goal of each step is to keep the person from becoming the point where contamination enters the preparation.

Because technique is central, sterile compounding personnel are trained and then evaluated on a recurring basis rather than certified once. Competency assessments described in the standards include direct observation of hand hygiene and garbing, gloved fingertip sampling, and media-fill testing, repeated at defined intervals. These checks are designed to confirm that a person's technique still meets the standard over time; they describe process and qualification, not any claim about a specific preparation's effect.

Quality controls that verify a sterile preparation

Beyond the room and the technique, sterile compounding relies on monitoring and testing to check that the controls are working. Environmental monitoring is one layer: viable air sampling and surface sampling are performed at defined intervals to detect microbial growth in the environment, and non-viable particle counts are used to confirm that a space still meets its ISO classification. The revised standards set how often this monitoring occurs, with higher-category compounding monitored more frequently.

Product-focused testing is another layer. Media-fill testing substitutes a sterile growth medium for the actual drug and runs it through the compounding process to challenge whether the technique keeps the preparation free of growth. For finished sterile preparations, sterility testing and bacterial endotoxin testing are used to check for contamination and for the byproducts of certain microbes. Outsourcing facilities that operate under Current Good Manufacturing Practice conduct potency and sterility testing as part of that framework; the distinction between patient-specific pharmacies and registered outsourcing facilities is covered in a separate guide on 503A and 503B categories.

One point sits underneath all of this: a compounded sterile preparation is not itself FDA-approved. The FDA approves finished, mass-manufactured drug products, not the individualized preparations a pharmacy compounds in response to a prescription. The cleanroom, the technique, and the testing described here are about contamination control and consistency under compounding rules — they are not a substitute for FDA approval, and they should not be read as one. Whether a compounded preparation is appropriate for a given person remains a clinical decision for a licensed provider, informed by that person's full medical picture.

How prescription review works on OpenDoseRx

Everything described in this article happens on the pharmacy side, and only after a clinical decision has already been made. On OpenDoseRx, you begin by choosing a product and strength, then complete a medical intake that collects your health history and other relevant information. That intake is routed to an independent, licensed U.S. provider who reviews it and decides whether a prescription is appropriate for you — a clinical judgment, not an automatic step.

If the provider determines a prescription is appropriate, it is sent to a licensed U.S. pharmacy, which prepares, verifies, and ships it under the standards described above. If the request is declined, your order does not proceed and you receive a full refund. Every product is prescription-only and is dispensed only after this independent review. This content is educational and procedural, and nothing here is a substitute for a conversation with your own healthcare provider.